Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series.

center dot The incidence of CNS metastases in patients with mUC either during or following treatment with enfortumab vedotin may be higher than previously reported in similar mUC cohorts. center dot CNS metastases in EV-treated patients with mUC are associated with inferior outcomes and limited systemic treatment options. center dot Poor outcomes associated with CNS metastases highlight the need for greater vigilance regarding CNS progression in the population of mUC patients treated with enfortumab vedotin and a reevaluation of the role of CNS imaging surveillance in this disease state. Clinical Genitourinary Cancer, Vol. 22, No. 2, 315-321 (c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )